pharmaceuticals
pharmaceuticals Articles
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
Published:
Last Updated:
Spring Bank Pharmaceuticals expects to price more than 2.8 million shares in the range of $13 to $15 per share in an IPO valued at up to more than $49 million.
Published:
Last Updated:
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
Published:
Last Updated:
In Monday's trading session, it seems that investors are finally coming around and trusting Valeant Pharmaceuticals.
Published:
Last Updated:
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
Published:
Last Updated:
Canaccord Genuity has downgraded Valeant Pharmaceuticals due to the growing uncertainty surrounding its multitude of investigations, both internal and external.
Published:
Last Updated:
Novavax reported disappointing fourth-quarter financial results before the markets opened on Monday.
Published:
Last Updated:
With investors looking for safety and dividends for total return, the big pharmaceutical stocks are just the ticket, and these four are outstanding.
Published:
Last Updated:
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
Published:
Last Updated:
Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell...
Published:
Last Updated:
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Published:
Last Updated:
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
Published:
Last Updated:
PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application for Translarna (ataluren).
Published:
Last Updated:
Syndax Pharmaceuticals expects to price more than 4 million shares in the range of $14 to $16 for an initial public offering valued up to almost $81 million.
Published:
Last Updated:
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
Published:
Last Updated: